Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 17457 | 535 | 47.3 | 93% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | HER3 | Author keyword | 15 | 33% | 7% | 39 |
| 2 | NUCLEAR EGFR | Author keyword | 12 | 75% | 2% | 9 |
| 3 | EGFR FAMILY | Author keyword | 11 | 69% | 2% | 9 |
| 4 | HER4 | Author keyword | 9 | 39% | 3% | 18 |
| 5 | ERBB3 | Author keyword | 9 | 21% | 7% | 37 |
| 6 | MORPHOL IMAGING CORE | Address | 6 | 71% | 1% | 5 |
| 7 | NRDP1 | Author keyword | 5 | 47% | 1% | 8 |
| 8 | FUJIAN TRANSPLANT BIOL | Address | 4 | 75% | 1% | 3 |
| 9 | PATRITUMAB | Author keyword | 4 | 75% | 1% | 3 |
| 10 | ERBB4 | Author keyword | 4 | 14% | 5% | 25 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | HER3 | 15 | 33% | 7% | 39 | Search HER3 | Search HER3 |
| 2 | NUCLEAR EGFR | 12 | 75% | 2% | 9 | Search NUCLEAR+EGFR | Search NUCLEAR+EGFR |
| 3 | EGFR FAMILY | 11 | 69% | 2% | 9 | Search EGFR+FAMILY | Search EGFR+FAMILY |
| 4 | HER4 | 9 | 39% | 3% | 18 | Search HER4 | Search HER4 |
| 5 | ERBB3 | 9 | 21% | 7% | 37 | Search ERBB3 | Search ERBB3 |
| 6 | NRDP1 | 5 | 47% | 1% | 8 | Search NRDP1 | Search NRDP1 |
| 7 | PATRITUMAB | 4 | 75% | 1% | 3 | Search PATRITUMAB | Search PATRITUMAB |
| 8 | ERBB4 | 4 | 14% | 5% | 25 | Search ERBB4 | Search ERBB4 |
| 9 | HER 3 | 4 | 30% | 2% | 10 | Search HER+3 | Search HER+3 |
| 10 | ERBB3 HER3 | 3 | 57% | 1% | 4 | Search ERBB3+HER3 | Search ERBB3+HER3 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | HER3 | 23 | 52% | 6% | 31 |
| 2 | INTRACELLULAR DOMAIN 4ICD | 21 | 85% | 2% | 11 |
| 3 | ERBB4 ISOFORM | 15 | 67% | 3% | 14 |
| 4 | EGFR FAMILY | 13 | 51% | 3% | 18 |
| 5 | ERBB3 | 12 | 27% | 7% | 39 |
| 6 | C ERBB 4 | 11 | 100% | 1% | 6 |
| 7 | ERBB FAMILY MEMBERS | 9 | 83% | 1% | 5 |
| 8 | ONCOGENIC UNIT | 6 | 71% | 1% | 5 |
| 9 | INACTIVE HER3 | 6 | 100% | 1% | 4 |
| 10 | CONSTITUTIVELY ACTIVE ERBB4 | 5 | 63% | 1% | 5 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Targeting of erbB3 receptor to overcome resistance in cancer treatment | 2014 | 9 | 96 | 48% |
| Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations | 2012 | 67 | 129 | 35% |
| HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis | 2013 | 28 | 36 | 44% |
| Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family | 2012 | 25 | 110 | 55% |
| The upgraded role of HER3 and HER4 receptors in breast cancer | 2010 | 27 | 48 | 71% |
| Nuclear trafficking of the epidermal growth factor receptor family membrane proteins | 2010 | 78 | 115 | 36% |
| Nuclear EGFR as a molecular target in cancer | 2013 | 17 | 63 | 44% |
| HER3, serious partner in crime Therapeutic approaches and potential biomarkers for effect of HER3-targeting | 2014 | 3 | 91 | 42% |
| Regulation of ERBB3/HER3 signaling in cancer | 2014 | 3 | 136 | 40% |
| Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival | 2006 | 136 | 46 | 33% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MORPHOL IMAGING CORE | 6 | 71% | 0.9% | 5 |
| 2 | FUJIAN TRANSPLANT BIOL | 4 | 75% | 0.6% | 3 |
| 3 | BEIJING HEART LUNG BLOOD VESSEL DISBEIJIN | 1 | 50% | 0.2% | 1 |
| 4 | DIPARTIMENTO SCI MED ORALI BIOTECNOL | 1 | 50% | 0.2% | 1 |
| 5 | ERTICA GRP | 1 | 50% | 0.2% | 1 |
| 6 | GROWTH TOR GRP ONCOL | 1 | 50% | 0.2% | 1 |
| 7 | HUMAN EPIDERMAL GROWTH TOR GRP ONCOL | 1 | 50% | 0.2% | 1 |
| 8 | IMPERIAL CANC FUND ONCOL UNIT | 1 | 50% | 0.2% | 1 |
| 9 | MOL CELLULAR DEV | 1 | 50% | 0.2% | 1 |
| 10 | MOL ONCOL UNITRECEPTOR BIOL | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000245938 | C ERBB 2//HER 2 NEU//P185 |
| 2 | 0.0000206274 | TRASTUZUMAB//LAPATINIB//PERTUZUMAB |
| 3 | 0.0000192028 | EBP1//RADIOBIOL CANC//PA2G4 |
| 4 | 0.0000153027 | IMMUNOGENE//MED MOLEC BIOL SHINJUKU KU//ERBB PROTEINS |
| 5 | 0.0000147965 | NIMOTUZUMAB//H R3//CETUXIMAB |
| 6 | 0.0000125207 | HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2//ADVANCED METASTATIC DISEASE//ANTI EGF RECEPTOR ANTIBODY |
| 7 | 0.0000116397 | WWP1//SMURF1//CKIP 1 |
| 8 | 0.0000093974 | DISC1//DYSBINDIN//NEUREGULIN 1 |
| 9 | 0.0000085075 | BREAST CARCINOMA CELL LINE//BIOTINYLATED EPIDERMAL GROWTH FACTOR//BREAST CANCER BIOPSIES |
| 10 | 0.0000083062 | HB EGF//HEPARIN BINDING EGF LIKE GROWTH FACTOR//HEPARIN BINDING EPIDERMAL GROWTH FACTOR LIKE GROWTH FACTOR |